The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Japan Enacts FY2022 Extra Budget, Reserves Nearly 4 Trillion Yen for COVID Response, Medical DX, Childcare
The second supplementary budget for the year through March 2023, which is to finance Japan’s new economic package, passed the parliament on December 2 with the House of Councilor’s blessing. Following the lower house’s clearance on November 29, the upper…
To read the full story
Related Article
- MHLW Reserves Extra Budget to Build Gene Therapy Support Consortium
November 11, 2022
- MHLW Earmarks 55 Billion Yen for Domestic Antibiotic API Production: Extra Budget
November 10, 2022
- JPMA Lauds Govt’s Proposed Extra Budget for Enhanced Startup Support
November 10, 2022
- Extra Budget to Cover Enough COVID Vaccine Purchases until Next Winter
November 10, 2022
- METI Looks to Bolster Pharma Startup Ecosystem with 6-Fold Hike in Extra Budget
November 10, 2022
REGULATORY
- LDP, Ishin Strike Deal on OTC-Like Drugs, Patients to Pay “1/4” Special Charge
December 22, 2025
- Japan Set to Raise Medical Fees by 3% in FY2026, Cut Drug Prices by 0.8%
December 22, 2025
- LDP, Ishin Finalize FY2026 Tax Reform Outline, Strategic Tech R&D Credit Codified
December 22, 2025
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…